
|Articles|September 27, 2014 (Updated: April 18, 2020)
- Head and Neck Cancers (Issue 2)
- Volume 2
- Issue 1
Sequencing Sorafenib and Lenvatinib in Thyroid Cancer
Author(s)Marcia S. Brose, MD, PhD, FASCO
Marcia S. Brose, MD, PhD, discusses using both sorafenib and lenvatinib as treatment options for thyroid cancer.
Articles in this issue
over 11 years ago
Treatment Update: Unresectable Medullary Thyroid Cancerover 11 years ago
The Side Effects of Lenvatinibover 11 years ago
Immune Checkpoint Inhibitors for Head and Neck Cancersover 11 years ago
Battling the Immunosuppressive Nature of Head and Neck CancerRelated Content
Advertisement



Safety and Antitumor Activity Revealed for T-Cell Engager XmAb819 in RCC
Published: | Updated:

Sarcomatoid Features May Be a Biomarker in Chromophobe RCC
Published: | Updated:

Vorasidenib Reduces Tumor Growth Rate in IDH1/2-Mutant Grade 2 Glioma
Published: | Updated:



























